STUDY SEARCH RESULTS

1 study found for your search request:  1088-002

A Study of MK-1088 as Monotherapy and in Combination with Pembrolizumab in Participants with Advance...
Condition: Advanced Solid Tumors
Minimum Age: 18 years, Maximum Age: N/A
Gender: All
Study ID: NCT05394350
Status: Terminated (Halted Prematurely)
Has Results




Copyright © 2026 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences  Privacy  Terms of Use  Consumer Health Data Privacy Policy  Your Privacy Choices   Accessibility  U.S. Corporate Site